


A Proposed Therapeutic Algorithm for CAD^{1-3,a}

PeerView Hematology



Full abbreviations, accreditation, and disclosure information available at PeerView.com/MVG40



a Sutimlimab was FDA approved in the United States in February 2022 and, of those agents listed, is the only agent with an indication for CAD. If Hb is high enough, watching and waiting may be a reasonable alternative in some cases. Blood transfusions should be given depending on the Hb level, preferentially with a blood warmer.

1. Jäger U et al. Blood Rev. 2020;41:100648. 2. Berentsen S. Blood. 2021;137:1295-1303. 3. https://coldagglutinindisease.org/treatment-options.